Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuesaitong soft capsule in Coronary Heart Disease
NCT03083119Phase 2Unknown
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xuesetong capsule in coronary heart disease (CHD) and unstable angina. Primary endpoint: Major Adverse Cardiovascular Events at 60 days. Status: unknown.
02
Drugs
xuesetong capsule
03
Conditions
coronary heart disease (CHD)unstable angina
Beyond the preview
Go deeper on NCT03083119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083119.